{"id":"nasal-glucagon-ng","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nasal irritation"}]},"_chembl":{"chemblId":"CHEMBL1944647","moleculeType":"Small molecule","molecularWeight":"5872.94"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Glucagon is a hormone that binds to glucagon receptors on hepatic cells, stimulating glycogenolysis and gluconeogenesis to raise blood glucose. The nasal formulation allows rapid absorption through the nasal mucosa, enabling quick glucose elevation without requiring intravenous administration. This provides a non-invasive alternative to injectable glucagon for acute hypoglycemia treatment.","oneSentence":"Nasal glucagon activates glucagon receptors to rapidly increase blood glucose levels in hypoglycemic emergencies.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:22:38.439Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Severe hypoglycemia in patients with diabetes"}]},"trialDetails":[{"nctId":"NCT03765502","phase":"PHASE1","title":"A Study Comparing User Experience of Different Delivery Devices for Glucagon","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-11-19","conditions":"Healthy","enrollment":99},{"nctId":"NCT02806960","phase":"PHASE1","title":"A Study of Single and Repeated Doses of Glucagon Administered to Participants With Diabetes","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2014-06","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":12},{"nctId":"NCT02806973","phase":"PHASE1","title":"A Study of Single or Repeated Doses of Glucagon in Participants With Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-01","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":32},{"nctId":"NCT01556594","phase":"PHASE2","title":"Safety and Efficacy of a Novel Glucagon Formulation in Type 1 Diabetic Patients Following Insulin-induced Hypoglycemia","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-03","conditions":"Hypoglycemia","enrollment":18},{"nctId":"NCT02778113","phase":"PHASE1","title":"A Study of Glucagon Administered in Different Forms and Routes to Healthy Adults","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-10","conditions":"Healthy","enrollment":16},{"nctId":"NCT02778100","phase":"PHASE1","title":"A Study of Nasal Glucagon in Participants With a Common Cold","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-03","conditions":"Common Cold","enrollment":36},{"nctId":"NCT01959334","phase":"PHASE3","title":"Evaluate the Immunogenicity of a Novel Glucagon Formulation","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-09","conditions":"Drug-specific Antibodies, Diabetes Mellitus","enrollment":75},{"nctId":"NCT01997411","phase":"PHASE2, PHASE3","title":"Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-11","conditions":"Diabetes Mellitus, Type 1","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Nasal Glucagon","AMG504-1 Dry-Mist Intranasal Glucagon","LY900018"],"phase":"phase_3","status":"active","brandName":"Nasal Glucagon (NG)","genericName":"Nasal Glucagon (NG)","companyName":"Eli Lilly and Company","companyId":"eli-lilly","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nasal glucagon activates glucagon receptors to rapidly increase blood glucose levels in hypoglycemic emergencies. Used for Severe hypoglycemia in patients with diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}